Saturday June 6, 2020

Amryt transforms itself with takeover of US pharma firm to develop key drugs

The chance to advance medicines for rare conditions such as EB, or butterfly skin, spurred the company on to make the acquisition

Ian Guider

Markets Editor

6th October, 2019
Dr Joe Wiley, chief executive of Amryt, says treatments for rare diseases are a growing market

Just over four years ago, Dr Joe Wiley set about building Amryt into a world leader in developing rare and orphan disease drugs. It came about via an unusual route: a reverse takeover of a tiny Dublin-based oil and gas exploration company called Fastnet that was looking for other opportunities. Fast forward four years and Amryt has just finalised a transformational takeover of an American drug company called Aegerion that will catapult it into the...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

The former NTMA head says he is ‘quite alarmed’ at the potential for legal actions over the large number of deaths in nursing homes during the crisis

Michael Brennan | 1 month ago

Oil storage in the self-styled ‘Pipeline Crossroads of the World’ is full to the brim, but the black stuff keeps on coming. With much of the world’s economy in a Covid-19 slowdown, at one point last week, benchmark US crude oil was priced at minus $37.63 a barrel

Barry J Whyte | 1 month ago

Every time Donald Trump spoke on the Covid-19 crisis last week, the stock markets plunged by another point

Marion McKeone | 2 months ago